Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Reteplase, myocardial infarction treatment

Plasminogen, an inactive precursor, is activated to plasmin which as a protease is able to break down fibrin clots. The thrombolytic agents in use promote the conversion of plasminogen to plasmin at the site of a thrombus. Indications include post-myocardial infarction treatment. The thrombolytic must be administered within 6 hours for an optimal effect. Other indications are treatment of acute pulmonary thromboembolism, deep-vein thrombosis, acute arterial thrombosis and thromboembolism, as well as in the clearance of arteriovenous catheters and can-nulae. Agents are streptokinase, anistreplase, urokinase, alteplase, reteplase and tenecteplase. [Pg.374]

Retevase Reteplase Boehringer Man Centocor Treatment of acute myocardial infarction... [Pg.695]

E Role in therapy Thrombolytic agents currently licensed for the treatment of AMI in the United States include streptokinase, tissue plasminogen activator, anistreplase, reteplase, and tenecteplase. TNKase and alteplase have similar clinical efficacy for thrombolysis after myocardial infarction (i.e., similar mortality and intracranial hemorrhage rates). However, advantages of TNKase include ease and rapidity of administration, longer half-life, greater fibrin specificity, and lower noncerebral bleeding rates. Reteplase shares some characteristics of tenecteplase (e.g., similar half-life, rapid onset, and ease of administration). [Pg.267]

Wooster MB, Luzier AB. Reteplase a new thrombolytic for the treatment of acute myocardial infarction. Ann Pharmacother. 1999 33 318-324. [Pg.366]


See other pages where Reteplase, myocardial infarction treatment is mentioned: [Pg.43]    [Pg.264]    [Pg.577]    [Pg.960]    [Pg.729]   
See also in sourсe #XX -- [ Pg.4 ]




SEARCH



Infarct

Infarct, myocardial

Infarction

Myocardial infarction

Myocardial infarction, treatment

Reteplase

© 2024 chempedia.info